Ventyx Biosciences Inc (VTYX) Stock Price, Quote & News

Company Profile

Ventyx Biosciences, Inc., a clinical-stage biopharmaceutical company, develops oral therapies for patients with autoimmune, inflammatory, and neurodegenerative diseases. The company's lead clinical product candidate is VTX958, a selective allosteric tyrosine kinase type 2 inhibitor for Crohn's disease. It is also developing Tamuzimod, a sphingosine 1 phosphate receptor modulator that is in Phase II clinical trials for the treatment of ulcerative colitis; and VTX2735, a peripheral NOD-like recept...

Industry: Biotechnology

Sector: Healthcare

Phone: 760 593 4832

Website: ventyxbio.com

Address:

12790 El Camino Real, Suite 200, San Diego, United States

isaacwilliams33 Dec. 5 at 5:46 PM

$VTYX cup 🥤

0 · Reply

Elevate1 Dec. 5 at 5:03 PM

$VTYX The institution that blew out 3000 Dec 10’s on Tuesday has resurfaced and increased his position and bought 5000 March 10’s. This makes the option market maker our friend again as it approached 10. I believe the market is caught short. Since 2735 is now considered a success I expect the bidding war premium will blow us through 10. Expect fireworks next week! I am long and will trade at will! Nlrp3 the king of the pharma world is apparent!

1 · Reply

Elevate1 Dec. 5 at 1:43 PM

$VTYX it Appears the analysts and institutions needed 4 days to convince themselves this is a hugely positive development for 2735! the CEO’s words reverberate truth “we have a drug!” Those words about a potential $1 billion / yr drug and further proof that VTYX is the class act in the next big drug class, NLRP3 inhibitors!, plus the dramatic results of 3232 mean the bidding war for this company is happening and will burst out very soon. When it does the world will be surprised at the value this company commands. We will break 10 with authority in days!I am long and will trade at will!

0 · Reply

vmst1 Dec. 4 at 5:19 PM

$VTYX The $BIOA result for its BGE-102 NLRP3 inhibitor showed great promise through double blinded randomized and placebo controlled phase 1 study. it has two implications for VTYX; NLRP3 appears to be almost proven pathway both for CNS and peripheral targets. And there would be competition for VTYX down the years. Perhaps VTYX decision to delay its Phase 2 recurrent pericarditis study is part of strategy to gain edge through global extension studies? VTYX does have lead in NLRP3 pathway drugs and BIOA result yesterday should help overcome doubts about slightly diminished VTYX potential long term future due to recently announced delay. I don't think NLRP3 inhibition works for weight loss indication as shown by VTYX in phase 2, so BIOA studies might settle that pre-clinical theory in coming months.

0 · Reply

MoneyGroupLLC Dec. 4 at 4:23 PM

Enter: $VTYX Calls Strike Price: $10 Expiry Date: JAN 16 2026 Buy in Price: $0.65 - $0.85 Sell Price: $1.29 Profit : +98% (Turn every $1 into $1.98) Want Profitable Real-Time Options Alerts? 👉 https://moneygroup.us

0 · Reply

Thesig556 Dec. 4 at 3:33 PM

$VTYX I think we pick up where we left off…,,, on othevesy past $10.54 on the way to the analysts targets and beyond……14, $16 & $18……..And higher ⚡️ Much higher than $18 ✨

0 · Reply

Diverstj981 Dec. 4 at 2:45 PM

$VTYX whew! Glad I took profits in the high 8's and 9's. Now I can buy 'em back cheap.

2 · Reply

Viktor4o Dec. 4 at 2:32 PM

$VTYX Unbelievable garbage

0 · Reply

Elevate1 Dec. 4 at 12:05 PM

$VTYX The CEO also was very demonstrative in saying that the major pharma companies and the pharma world know very well the results of their nlrp3 products which are at least two years ahead of any competitors! I go back to my insistence that NVO has no choice but to try to buy this company. All of my and SOD2’s research shows that the nlrp3 inhibitors will be the next class of drugs that will get the public and pharma investors’s attention! VTYX , more probably a part of LLY, NVO, SNY , JNJ or Roche will be the leader! I am long and will trade at will. PS, I still firmly believe the end point of the imminent bidding war is $150-200/ shr

0 · Reply

HedgeAlerts Dec. 4 at 7:41 AM

Hedge Alert Live - Protect Your Portfolio Contract: $VTYX $7.50 Put · DEC 19, 2025 Exp Entry Price: $0.44 - $0.50 Exit Price Target: $0.76 Profit Margin: +73% Hold Period: 1-3 days MAX ONLY USE THESE ALERTS ON RED/DOWN MARKET DAYS. Monetize Red Market Days: https://hedgealerts.com

0 · Reply

Ventyx Provides Clinical and Corporate Updates

Dec 1, 2025, 7:02 AM EST - 4 days ago

Ventyx Biosciences to Participate in the Piper Sandler 37th Annual Healthcare Conference

Nov 17, 2025, 7:02 AM EST - 18 days ago

Ventyx Biosciences to Participate in the Jefferies Global Healthcare Conference in London

Nov 6, 2025, 4:02 PM EST - 4 weeks ago

Ventyx Biosciences Reports Third Quarter 2025 Financial Results and Highlights Recent Corporate Progress

Oct 24, 2025, 2:17 AM EDT - 6 weeks ago

Ventyx Biosciences, Inc. (VTYX) Discusses Positive Phase II Results of VTX3232 in Obesity and Cardiovascular Risk Factors Transcript

Oct 22, 2025, 4:02 PM EDT - 6 weeks ago

Ventyx Biosciences Announces Positive Topline Results from Phase 2 Study of VTX3232 in Participants with Obesity and Cardiovascular Risk Factors

Aug 27, 2025, 7:02 AM EDT - 3 months ago

Ventyx Biosciences to Participate in Three Upcoming Investor Conferences

Aug 7, 2025, 5:47 PM EDT - 4 months ago

Ventyx (VTYX) Q2 Net Loss Drops 16%

Aug 7, 2025, 4:05 PM EDT - 4 months ago

Ventyx Biosciences Reports Second Quarter 2025 Financial Results and Highlights Recent Corporate Progress

Jun 17, 2025, 7:00 AM EDT - 6 months ago

Ventyx Biosciences Announces Positive Top-Line Data from its Phase 2a Safety and Biomarker Trial Evaluating VTX3232 in Patients with Early-Stage Parkinson's Disease

May 28, 2025, 8:00 AM EDT - 6 months ago

Ventyx Biosciences to Participate in the Jefferies Global Healthcare Conference

May 8, 2025, 4:01 PM EDT - 7 months ago

Ventyx Biosciences Reports First Quarter 2025 Financial Results and Highlights Recent Corporate Progress

Apr 1, 2025, 7:00 AM EDT - 8 months ago

Ventyx Biosciences Expands SAB with Renowned NLRP3 Experts and Prominent Neurodegenerative and Cardiometabolic Disease Specialists

Feb 27, 2025, 4:05 PM EST - 10 months ago

Ventyx Biosciences Reports Fourth Quarter and Full Year 2024 Financial Results and Highlights Recent Corporate Progress

Feb 18, 2025, 8:00 AM EST - 10 months ago

Ventyx Biosciences Announces Presentation of Data from the Phase 2 Trial of Allosteric TYK2 Inhibitor VTX958 in Crohn's Disease at ECCO 2025

Feb 5, 2025, 8:00 AM EST - 10 months ago

Ventyx Biosciences to Participate in the Oppenheimer 35th Annual Healthcare Life Sciences Conference

Jan 14, 2025, 8:00 AM EST - 11 months ago

Ventyx Biosciences Highlights 2025 Pipeline Strategy and Provides Clinical Updates on its NLRP3 Inhibitor Portfolio

Nov 4, 2024, 10:32 AM EST - 1 year ago

Ventyx Biosciences: Ready To Escape "The Crash Cycle"

Sep 23, 2024, 11:13 AM EDT - 1 year ago

Sanofi Injects $27M In Neurology Drug Developer Ventyx Biosciences

SNY

Sep 6, 2024, 8:00 AM EDT - 1 year ago

Ventyx Biosciences Announces Initiation of Dosing in a Phase 2a Trial of VTX3232 in Patients with Early Parkinson's Disease

Aug 30, 2024, 8:00 AM EDT - 1 year ago

Ventyx Biosciences Announces Departure of Chief Financial Officer

Aug 28, 2024, 8:00 AM EDT - 1 year ago

Ventyx Biosciences to Participate in Two Upcoming Investor Conferences

Aug 8, 2024, 4:01 PM EDT - 1 year ago

Ventyx Biosciences Reports Second Quarter 2024 Financial Results and Highlights Recent Corporate Progress

Jul 29, 2024, 2:31 PM EDT - 1 year ago

Dow Edges Lower; Ventyx Biosciences Shares Plummet

Jul 29, 2024, 11:03 AM EDT - 1 year ago

Ventyx Biosciences' Inflammatory Bowel Disease Candidate Flunks In Mid-Stage Study, Company Looks For Partner To Pursue It Further

Jun 24, 2024, 6:00 AM EDT - 1 year ago

VENTYX INVESTOR UPDATE: Ventyx's (Nasdaq:VTYX) Board is Being Investigated for Insider Trading, Long-term Investors Are Urged to Contact the Firm for Details

Jun 21, 2024, 4:15 PM EDT - 1 year ago

VENTYX INVESTOR NOTICE: Ventyx's (NASDAQ:VTYX) Board is Being Investigated for Insider Trading Allegations, Long-term Investors Are Urged to Contact the Firm for Details

Jun 20, 2024, 7:20 AM EDT - 1 year ago

VENTYX INVESTOR REMINDER: Ventyx (Nasdaq:VTYX) Shareholders are Urged to Contact BFA Law about its Review of the Board's Insider Trading Scheme

Jun 19, 2024, 4:20 PM EDT - 1 year ago

VENTYX INVESTIGATION REMINDER: Ventyx (Nasdaq:VTYX) Investors are Urged to Contact BFA Law about Inquiry into the Board for its Insider Trading Scheme and Avoiding Losses

Jun 18, 2024, 3:42 PM EDT - 1 year ago

VENTYX INSIDER TRADING INQUIRY: Ventyx (VTYX) Shareholders are Urged to Contact BFA Law about Investigation into the Board for Insider Trading Scheme and Avoiding Losses

Jun 17, 2024, 6:32 AM EDT - 1 year ago

VENTYX NOTIFICATION: Ventyx (VTYX) Shareholders are Encouraged to Contact BFA Law about Investigation into the Board for Insider Trading Scheme and Avoiding Substantial Losses

Jun 13, 2024, 4:06 PM EDT - 1 year ago

BFA Law Notice: Ventyx (Nasdaq: VTYX) Shareholders are Encouraged to Contact the Firm about Investigation into the Board for Insider Trading Scheme and Avoiding Substantial Losses

Jun 13, 2024, 7:13 AM EDT - 1 year ago

VENTYX REMINDER: BFA Law is Investigating Ventyx (Nasdaq: VTYX) Directors for Insider Trading Scheme and Avoiding Substantial Losses, Shareholders are Urged to Contact the Firm

Jun 12, 2024, 4:04 PM EDT - 1 year ago

STOCK DROP NOTICE: Ventyx (Nasdaq:VTYX) Stock Drops 20%, Investors are Encouraged to Contact BFA Law about the Investigation into the Company's Board for Insider Trading

Jun 11, 2024, 3:37 PM EDT - 1 year ago

VENTYX STOCK NOTICE: Ventyx (Nasdaq:VTYX) Stock Drops 20%, Shareholders are Reminded to Contact BFA Law about the Investigation into the Company's Board of Directors

Jun 11, 2024, 6:41 AM EDT - 1 year ago

VENTYX INVESTIGATION ANNOUNCEMENT: Ventyx (Nasdaq: VTYX) Stock Drops 20%, Investors are Urged to Contact BFA Law about the Investigation into the Company's Board

Jun 8, 2024, 5:24 AM EDT - 1 year ago

VENTYX NEWS NOTICE: Ventyx (Nasdaq: VTYX) Shareholders are Urged to Contact BFA Law about the Investigation into the Company's Board of Directors

Jun 5, 2024, 4:01 PM EDT - 1 year ago

Ventyx Biosciences Announces Positive Preclinical Data for CNS-Penetrant NLRP3 Inhibitor VTX3232 Demonstrating Reversal of Obesity and Improvements in Cardiometabolic and Inflammatory Markers

May 16, 2024, 8:00 AM EDT - 1 year ago

Ventyx Biosciences Announces Appointment of Matthew Moore as Chief Operating Officer

May 11, 2024, 1:58 PM EDT - 1 year ago

Ventyx Biosciences, Inc. (VTYX) Q1 2024 Earnings Call Transcript

May 2, 2024, 4:05 PM EDT - 1 year ago

Ventyx Biosciences to Report First Quarter 2024 Financial Results on May 9, 2024

isaacwilliams33 Dec. 5 at 5:46 PM

$VTYX cup 🥤

0 · Reply

Elevate1 Dec. 5 at 5:03 PM

1 · Reply

Elevate1 Dec. 5 at 1:43 PM

0 · Reply

vmst1 Dec. 4 at 5:19 PM

0 · Reply

MoneyGroupLLC Dec. 4 at 4:23 PM

0 · Reply

Thesig556 Dec. 4 at 3:33 PM

$VTYX I think we pick up where we left off…,,, on othevesy past $10.54 on the way to the analysts targets and beyond……14, $16 & $18……..And higher ⚡️ Much higher than $18 ✨

0 · Reply

Diverstj981 Dec. 4 at 2:45 PM

$VTYX whew! Glad I took profits in the high 8's and 9's. Now I can buy 'em back cheap.

2 · Reply

Viktor4o Dec. 4 at 2:32 PM

$VTYX Unbelievable garbage

0 · Reply

Elevate1 Dec. 4 at 12:05 PM

0 · Reply

HedgeAlerts Dec. 4 at 7:41 AM

0 · Reply

Elevate1 Dec. 3 at 10:44 PM

$VTYX Having listened to his 30 min podcast I will now translate a geeky answer from our very accomplished and educated CEO. I repeat the most important thing he said” we have a drug!” In phase 2 A with 10 people to move the 2a trial to in a sense make it 2 b and speed to phase three this is a major justification on the 1x a day drug lasting beyond 13 weeks. This is huge. He said the pharma guys looking at him understand this. So I ask he is telling you he is conversing with appropriate strategic players. Despite his low key presentation. His voice raised when he said he has a drug! Also when he said the pharma cos know all about his products. We should go back to realizing NVO, and lly need to buy the leading nlrp3 co! I am long and will trade at will

3 · Reply

Radzimgopkj Dec. 3 at 10:10 PM

$VTYX The “countdown” on the negotiation window began after Ventyx provided Sanofi with the data package for the two key 3232 studies – namely the Phase 2a trial in Parkinson’s and the Phase 2 OBesity trial in cardiometabolic inflammation. As Mohan mentioned, these data were already handed over to Sanofi at the end of 2025. Sanofi now has a limited timeframe — on the order of a few months — to make its decision.

0 · Reply

Viktor4o Dec. 3 at 8:26 PM

$VTYX Elevate1 is a paid basher 🤡🤡🤡

2 · Reply

Viktor4o Dec. 3 at 6:08 PM

$VTYX Seems to me nothing happens, dead cat bounce 🥺

0 · Reply

Elevate1 Dec. 3 at 1:05 PM

$VTYX It amazes me that the market is totally reading yesterday’s 2735 update wrong! There is no way a Company goes to once a day dosing and moves the 2a design trial to incorporate more centers in more countries to actually make it work like a 2b trial if there was not significant efficacy! Companies do not waster $ on failed trials. They moved it from 13 to 24 weeks to match the competitive products trial test . However they are now a once a day pill( obviously does not cause much side effects) vs the once a week injection. Significantly better compliance and ease of use. That update was a major win for shareholders and for the takeover value of this company! I expect his 430 fireside chat tonight will back this up. This is a major buying opportunity! I am and as always will trade at will!

1 · Reply

MoneyGroupLLC Dec. 3 at 9:28 AM

Enter: $VTYX Calls Strike Price: $10 Expiry Date: JAN 16 2026 Buy in Price: $2.33 - $2.45 Sell Price: $3.66 Profit : +57% (Turn every $1 into $1.57) Want Profitable Real-Time Options Alerts? 👉 https://moneygroup.us

0 · Reply

Radzimgopkj Dec. 3 at 9:12 AM

$VTYX In my view, yesterday’s news about pushing things into next year is actually very positive. If there were problems: ⛔ they wouldn’t be touching the protocol ⛔ they wouldn’t be adding international sites ⛔ they wouldn’t be moving to QD dosing ⛔ they wouldn’t be extending the trial to 24 weeks All of this signals that the company is confident in the safety profile and is expecting a meaningful effect.

0 · Reply

AL_007_ Dec. 3 at 12:40 AM

$VTYX anyone good with charts? Seems like a similar setup to 1Q24. May keep falling? Best to wait and watch and accumulate around $5-$6?

0 · Reply

msp3501 Dec. 2 at 10:37 PM

$VTYX Bargin bin discount. I'll buy some more please and thank you.

0 · Reply

OX50 Dec. 2 at 10:17 PM

$VTYX

0 · Reply

NSAR Dec. 2 at 7:21 PM

$VTYX why is it down today? I have not been paying attention.

1 · Reply

OX50 Dec. 2 at 7:07 PM

$VTYX Latest Report 12/02/2025 LSEG maintains a current price target of $13.71 for VTYX

0 · Reply

Market Cap	559.46M
Revenue (ttm)	0.00
Net Income (ttm)	-135.12M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	0.00%
Debt to Equity Ratio	0.00

Volume	2,229,566
Avg Vol	5,142,816
Day's Range	N/A - N/A
Shares Out	71.36M
Stochastic %K	14%
Beta	1.22
Analysts	Strong Sell
Price Target	$15.14